论文部分内容阅读
目的评价国内有关米力农治疗国人慢性阻塞性肺疾病心力衰竭疗效及安全性。方法计算机检索中国生物医学文献数据库、中国期刊全文数据库、万方数据库、重庆维普数据库等中文数据库,以“米力农”、“心力衰竭”、“肺源性心脏病”为关键词,手工检索部分中文文献,文献检索年限2005~2013年,收集有关米力农治疗国人慢性阻塞性肺疾病心力衰竭的随机对照试验,有两名评价员检索资料并交叉核对,利用Cochrane系统评价手册中的质量评价量表,对纳入的所有随机对照试验(RCT)文献进行质量评分;统计学处理采用Cochrane协作网的RevMan 4.2软件进行Meta分析。结果初步检索相关文献275篇,阅读全文及质量评价后,最终纳入9项研究,包括患者612例,米力农治疗组314例,对照组298例,米力农治疗组临床有效率明显高于对照组,其差异有统计学意义。结论米力农对国人慢性阻塞性肺疾病心力衰竭有明显疗效,短期用药不良反应少,比较安全;本研究仅能说明米力农短期临床疗效满意,米力农远期疗效如何还待进一步研究探讨。但由于国内大部分文献方法学质量差,同时因对不良反应观察样本数有限,这一结论尚需更多设计严格的高质量研究加以证实。
Objective To evaluate the efficacy and safety of milrinone in the treatment of chronic obstructive pulmonary disease in our country. Methods The Chinese database of Chinese biomedical literature database, Chinese periodical full-text database, Wanfang database and Chongqing VIP database were searched by computer, and the Chinese databases of “Milrinone”, “Heart Failure” and “Pulmonary Heart Disease” As the key words, part of the manual search of Chinese literature, literature retrieval years from 2005 to 2013, the collection of milrinone treatment of chronic obstructive pulmonary disease in Chinese people with heart failure randomized controlled trials, two reviewers retrieve the data and cross-check, the use of Cochrane The quality evaluation questionnaire in the systematic review manual scored quality scores for all RCTs included in the review; statistical analysis was performed using the Cochrane Collaboration’s RevMan 4.2 software for Meta-analysis. Results A total of 275 articles were searched initially. After reading the full text and evaluating the quality, 9 studies were finally included, including 612 patients, 314 patients in Milrinone treatment group and 298 patients in control group. Clinical efficacy of Milrinone treatment group was significantly higher than The control group, the difference was statistically significant. Conclusion Milrinone has obvious curative effect on heart failure of chronic obstructive pulmonary disease in our country and short-term adverse drug reaction is safe and safe. This study only shows that milrinone has satisfactory short-term clinical efficacy and how long-term efficacy of milrinone still needs further study Discussion. However, due to the poor methodology of most domestic literatures and the limited number of samples observed for adverse reactions, this conclusion still needs to be confirmed by more well-designed and high-quality studies.